Malin’s underlying share price jumps 20% after investment in US cancer firm surges

The life sciences investment company, which is backed by Isif, has seen its underlying share price jump to €7.91 in the opening months of 2024

Malin Corporation holds minority stakes in a number of life science and biotech companies. Picture: Paul Nunberg

Malin Corporation, the state-backed life sciences investment company, saw its cash balance fall to less than €30 million at year-end 2023, after the listed firm returned more than €140 million to shareholders by way off a tender offer share buyback last year.

Announcing results for its 2023 financial year, the company said the estimated fair value of its shares stood at €6.56 at the end of December, which is down 30 per cent on the ...